Skip to main content

CCTG at ASH 2026

CCTG at ASH 2026

CCTG at the 68th ASH Annual Meeting and Exposition was hosted by the American Society of Hematology (ASH) December 12–15, 2026 New Orleans, Louisiana.


CCTG IND.244 — A Phase 2 Study of Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary Central Nervous System Lymphoma

Type:             Poster

Session:         627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II

Abstract:       IND.244: A Canadian cancer trials group Phase 2 study of ibrutinib combination therapy in transplant ineligible individuals with newly diagnosed primary central nervous system lymphoma 

Abstract #:    3672

Authors:        Comelles MF, Larouche JF, Prica A, Villa D, Puckrin R, Davison K, Macdonald D, Fraser G, Eswedi A, Cowan A, Savage K, Sehn LH, Owen C, Tampieri D, Islam O, Rullo J, Urton T, Mendonza N, Kridel R, Tu W, Hay A.

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=688875

Citation:        TBC

 

 

CCTG ALC.4 / ECOG-ACRIN E1910 — A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Type:             Oral

Session:         613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Frontline Therapy in Acute Lymphoblastic Leukemia: At the Crossroads of Chemotherapy, Immunotherapy, and Targeted Therapy Across the Age Spectrum

Abstract:       Blinatumomab reduces risk of relapse and improves overall survival in NGS MRD negative BCR::ABL1 negative precursor B-cell acute lymphoblastic leukemia in randomized patients on the E1910 Phase III trial

Abstract #:    1000

Authors:        Pratz KW, Sun Z, Mattison RJ, Paietta EM, Mullighan CG, Roberts KG, Zhong X, Tatevossian RG, Jia S, Zhang Y, Racevskis J, Willman CL, Wieduwilt MJ, Liedtke M, Bergeron J, Lazarus HM, Arber D, Wood BL, Rowe J, Dinner S, Frey N, Gore S, Podoltsev N, Bhatnagar B, Atallah E, Uy GL, Jeyakumar D, Lin TL, Patel S, Elliott M, Advani AS, DeAngelo DJ, Tzachanis D, Vachhani P, Bhave RRR, Mourad YA, Shami PJ, Baer MR, Asch A, O'Dwyer K, Hall A, Little RF, Erba HP, Stone R, Tallman M, Luger S, Litzow MR.

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=691581

Citation:        TBC

 

 

myeloMATCH — Master Screening and Reassessment Protocol for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Type:             Poster

Session:         618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster I

Abstract:       High success rate for rapid cytogenetic test and factors contributing to failed karyotype analysis - an NCI myelomatch and SWOG report on the first 1000 enrolled patients 

Abstract #:    1698

Authors:        McClung S, Kroeger K, Othus M, Qu X, Biggerstaff JS, Gurung S, Wood B, Yeung CCS, Harris L, Litzow MR, Erba H, Radich J, Jiwani S, Little RF, Fang M

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=693061

Citation:        TBC

 

 

CCTG AL.6 / MM1YA-CTG01 — A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Substudy]

Type:             Poster

Session:         617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III

Abstract:       A measurable residual disease (MRD) driven, phase II study of venetoclax plus chemotherapy for newly diagnosed younger patients with intermediate risk acute myeloid leukemia: A myelomatch substudy (MM1YA-CTG01) 

Abstract #:    5169

Authors:        Savoie ML, Chen B, Carlson KS, Mantzaris I, Male H, Espinoza-Gutarra MR, Odenike O Jr, McDonald G, Shepherd L, Stone R, Luger S, Erba H, Litzow MR, Little RF, Atallah E, Othus M, Assouline SE

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=692310

Citation:        TBC

 

 

CCTG ALC.8 / MM1YA-S01 — A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A MyeloMATCH Substudy

Type:             Poster

Session:         615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I

Abstract:       Trial in progress: A randomized phase II study comparing cytarabine + daunorubicin (7+3) vs (Daunorubicin and Cytarabine) liposome, cytarabine + daunorubicin + venetoclax, azacitidine + venetoclax, and (Daunorubicin and Cytarabine) liposome + venetoclax in patients aged 59 or younger who are considered high-risk acute myeloid leukemia as determined by myelomatch; A myelomatch substudy - MM1YA-S01 

Abstract #:    1577

Authors:        Shami PJ, Othus M, Lin TL, Richard-Carpentier G Sr, Cerny J, Reed D, O'Dwyer K, Mohty R, Assi R, Atallah E, Winer ES, Wood B, Fang M, Yeung CCS, Radich J, Jiwani S, Gore S, Harris L, Little RF, Erba H

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=692305

Citation:        TBC

 

 

CCTG ALC.10 / MM1OA-EA02 — A Randomized Phase II Study of Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A myeloMATCH Substudy

Type:             Poster

Session:         616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I

Abstract:       MM1OA-EA02: A randomized phase II study of venetoclax and HMA-based therapies for the treatment of older and unfit adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)--a myelomatch substudy

Abstract #:    1627

Authors:        Altman JK, Sun Z, Perl AE, Chen L, Reagan J, Turk A, Michaelis LC, Gore S, Little RF, Jiwani S, Radich J, Uy GL, Litzow MR, Luger S

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=692306

Citation:        TBC

 

 

CCTG ALC.11 / SWOG MM1OA-S03 — A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy

Type:             Poster

Session:         617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I

Abstract:       A safety run-in of decitabine/cedazuridine, venetoclax, and enasidenib for newly diagnosed IDH2-mutated AML: The myelomatch MM1OA-S03 study 

Abstract #:    1655

Authors:        Huselton E, Othus M, Borate U, Reagan J, Little RF, Gore S, Moseley A, Pelosof L, Pandey M, Wang X, Thompson J, Patel AA, Wilde L, Fang M, Radich J, Yeung CCS, Jiwani S, Michaelis LC, Uy GL, Advani AS, Erba H 

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=692977

Citation:        TBC

 

 

CCTG CLC.2 / Alliance A041202 — A Randomized Phase III Comparison of Bendamustine-Rituximab Versus Ibrutinib-Based Regimens in Untreated Older Patients with Chronic Lymphocytic Leukemia

Type:             Oral

Session:         642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Initial CLL Treatment Strategies with Targeted Agent Combinations and MRD-guidance

Abstract:       Final Results of Alliance A041202 demonstrate continued superiority of ibrutinib-containing regimens vs chemoimmunotherapy and durable remissions induced by ibrutinib in previously untreated older patients with chronic lymphocytic leukemia 

Abstract #:    814

Authors:        Woyach JA, Perez Burbano G, Miller CR, Heerema N, Zhao W, Wall A, Ding W, Atallah E, Bartlett NL, Brander D, Barr PM, Rogers KA, Parikh SA, Stephens D, Brown JR, Lozanski G, Blachly JS, Nattam S, Larson RA, Erba HP, Litzow MR, Luger S, Owen C, Kuzma C, Abramson JS, Little RF, Dinner S, Stone RM, Uy GL, Stock W, Mandrekar S, Byrd J

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=683309

Citation:        TBC

 

 

CCTG HDC.1 / SWOG S1826 — A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Type:             Oral

Session:         624. Hodgkin Lymphomas: Clinical and Epidemiological: Precision, Prognostication, and Paradigm Shifts

Abstract:       Individual patient data comparison of BrECADD and nivolumab-AVD in advanced-stage classic Hodgkin lymphoma: A joint GHSG/SWOG analysis of HD21 and S1826 

Abstract #:    1021

Authors:        Ferdinandus J, Herrera AF, Jablonski J, Li H, Leblanc M, Kaul H, Smith S, Fuchs M, Borchmann P, Friedberg JW 

Link:               https://onlineprogram.hematology.org/paper-details.aspx?pid=688980

Citation:        TBC